Fig. 4From: Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancerEffect of previous immune checkpoint inhibitor (ICI) administration on COVID-19 prognosis in patients with lung cancer. Patients were categorized into four groups: within 90 days from last ICI administration to COVID-19 diagnosis, 91–180 days, > 180 days, and non-ICI group, and the mortality rate for each group is indicatedBack to article page